AnaptysBio (ANAB) Financials

$22.45 -0.11 (-0.49%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$22.23 -0.22 (-0.98%)

As of 05/30/2025 04:21 PM Eastern

Annual Income Statements for AnaptysBio

This table shows AnaptysBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-145	-164	-129
Consolidated Net Income / (Loss)	-145	-164	-129
Net Income / (Loss) Continuing Operations	-145	-164	-129
Total Pre-Tax Income	-145	-164	-129
Total Operating Income	-115	-164	-115
Total Gross Profit	91	17	10
Total Revenue	91	17	10
Operating Revenue	91	17	10
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	206	182	125
Selling, General & Admin Expense	42	42	37
Research & Development Expense	164	140	89
Total Other Income / (Expense), net	-30	0.79	-14
Interest Expense	50	18	21
Interest & Investment Income	20	19	7.55
Other Income / (Expense), net	0.01	-0.00	0.01
Income Tax Expense	0.00	-0.00	0.02
Basic Earnings per Share	($5.12)	($6.08)	($4.57)
Weighted Average Basic Shares Outstanding	28.38M	26.92M	28.17M
Diluted Earnings per Share	($5.12)	($6.08)	($4.57)
Weighted Average Diluted Shares Outstanding	28.38M	26.92M	28.17M
Weighted Average Basic & Diluted Shares Outstanding	30.67M	26.76M	27.93M

This table shows AnaptysBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-22	-33	-47	-44	-42	-37	-40	-44	-26	-34
Consolidated Net Income / (Loss)	-22	-33	-47	-44	-42	-37	-40	-44	-26	-34
Net Income / (Loss) Continuing Operations	-22	-33	-47	-44	-42	-37	-40	-44	-26	-34
Total Pre-Tax Income	-22	-33	-47	-44	-42	-37	-40	-44	-26	-34
Total Operating Income	-9.67	-23	-40	-42	-42	-38	-40	-44	-26	-30
Total Gross Profit	43	30	11	7.18	9.01	3.32	3.46	1.37	6.81	1.29
Total Revenue	43	30	11	7.18	9.01	3.32	3.46	1.37	6.81	1.29
Operating Revenue	43	30	11	7.18	9.01	3.32	3.46	1.37	6.81	1.29
Total Operating Expenses	53	53	51	49	51	41	44	46	33	31
Selling, General & Admin Expense	10	11	9.30	12	10	10	11	11	9.41	8.86
Research & Development Expense	43	42	42	37	41	31	33	35	23	22
Total Other Income / (Expense), net	-12	-10	-6.33	-1.74	-0.08	0.42	0.30	0.15	-0.42	-3.87
Interest Expense	17	15	11	6.32	4.96	4.43	4.36	4.34	4.25	6.14
Interest & Investment Income	5.26	5.32	4.62	4.58	4.88	4.85	4.65	4.49	3.84	2.26
Other Income / (Expense), net	0.02	-0.01	0.00	-0.00	-0.00	0.00	0.00	-0.00	-0.00	0.00
Basic Earnings per Share	($0.63)	($1.14)	($1.71)	($1.64)	($1.59)	($1.41)	($1.50)	($1.58)	($0.93)	($1.18)
Weighted Average Basic Shares Outstanding	28.38M	28.89M	27.36M	26.80M	26.92M	26.55M	26.63M	27.95M	28.17M	28.29M
Diluted Earnings per Share	($0.63)	($1.14)	($1.71)	($1.64)	($1.59)	($1.41)	($1.50)	($1.58)	($0.93)	($1.18)
Weighted Average Diluted Shares Outstanding	28.38M	28.89M	27.36M	26.80M	26.92M	26.55M	26.63M	27.95M	28.17M	28.29M
Weighted Average Basic & Diluted Shares Outstanding	30.67M	30.43M	27.45M	27.32M	26.76M	26.58M	26.55M	26.49M	27.93M	28.43M

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	87	-35	-424
Net Cash From Operating Activities	-135	-121	-74
Net Cash From Continuing Operating Activities	-135	-121	-74
Net Income / (Loss) Continuing Operations	-145	-164	-129
Consolidated Net Income / (Loss)	-145	-164	-129
Depreciation Expense	0.61	0.65	0.68
Amortization Expense	1.79	1.72	1.66
Non-Cash Adjustments To Reconcile Net Income	40	35	45
Changes in Operating Assets and Liabilities, net	-32	5.11	7.38
Net Cash From Investing Activities	95	145	-395
Net Cash From Continuing Investing Activities	95	145	-395
Purchase of Property, Plant & Equipment	-0.36	-0.81	-0.36
Purchase of Investments	-380	-304	-803
Sale and/or Maturity of Investments	476	449	408
Net Cash From Financing Activities	127	-59	44
Net Cash From Continuing Financing Activities	127	-59	44
Repurchase of Common Equity	-0.95	-50	0.00
Issuance of Common Equity	6.47	2.47	12
Other Financing Activities, net	122	-12	32
Cash Interest Paid	42	0.00	0.00

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-69	120	18	18	9.67	-8.91	-59	23	13	-13
Net Cash From Operating Activities	-67	-10	-21	-37	-34	-36	-25	-25	-11	-18
Net Cash From Continuing Operating Activities	-67	-10	-21	-37	-34	-36	-25	-25	-11	-18
Net Income / (Loss) Continuing Operations	-22	-33	-47	-44	-42	-37	-40	-44	-26	-34
Consolidated Net Income / (Loss)	-22	-33	-47	-44	-42	-37	-40	-44	-26	-34
Depreciation Expense	0.15	0.14	0.15	0.16	0.17	0.16	0.16	0.17	0.18	0.17
Amortization Expense	0.46	0.45	0.44	0.44	0.44	0.43	0.42	0.43	1.21	-0.37
Non-Cash Adjustments To Reconcile Net Income	-5.28	18	14	13	6.33	9.16	8.94	11	8.19	13
Changes in Operating Assets and Liabilities, net	-40	4.32	11	-7.16	0.93	-8.92	4.91	8.19	6.15	2.96
Net Cash From Investing Activities	-29	59	-2.44	69	49	31	-20	85	21	-32
Net Cash From Continuing Investing Activities	-29	59	-2.44	69	49	31	-20	85	21	-32
Purchase of Property, Plant & Equipment	-0.26	-0.04	-0.03	-0.03	-0.28	-0.16	-0.19	-0.18	-0.18	-0.05
Purchase of Investments	-121	-51	-149	-59	-66	-70	-119	-49	-128	-180
Sale and/or Maturity of Investments	92	110	147	128	116	101	99	134	149	148
Net Cash From Financing Activities	28	71	42	-14	-5.16	-3.07	-13	-38	1.95	37
Net Cash From Continuing Financing Activities	28	71	42	-14	-5.16	-3.07	-13	-38	1.95	37
Repurchase of Common Equity	-0.58	-0.37	-	0.00	-	-	-12	-38	-	-
Issuance of Common Equity	0.56	4.13	0.98	0.81	0.26	0.16	0.78	1.27	3.42	2.70
Other Financing Activities, net	27	68	41	-14	-5.47	-3.23	-1.80	-1.27	-1.76	35

This table presents AnaptysBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	484	452	610
Total Current Assets	432	407	447
Cash & Equivalents	123	36	71
Short-Term Investments	262	355	370
Accounts Receivable	41	6.85	1.42
Prepaid Expenses	5.74	9.08	4.55
Plant, Property, & Equipment, net	1.85	2.10	2.09
Total Noncurrent Assets	50	43	161
Long-Term Investments	35	27	143
Other Noncurrent Operating Assets	15	16	18
Total Liabilities & Shareholders' Equity	484	452	610
Total Liabilities	413	364	348
Total Current Liabilities	45	37	26
Accounts Payable	4.00	4.70	2.78
Accrued Expenses	40	31	22
Other Current Liabilities	1.93	1.78	1.64
Total Noncurrent Liabilities	368	327	322
Other Noncurrent Operating Liabilities	368	327	322
Total Equity & Noncontrolling Interests	71	88	262
Total Preferred & Common Equity	71	88	262
Preferred Stock	0.00	0.00	0.00
Total Common Equity	71	88	262
Common Stock	830	703	718
Retained Earnings	-759	-614	-450
Accumulated Other Comprehensive Income / (Loss)	0.31	-0.80	-5.25

This table presents AnaptysBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	493	427	406	487	517	552	619
Total Current Assets	449	367	372	428	439	437	450
Cash & Equivalents	192	72	54	26	35	95	59
Short-Term Investments	239	279	301	387	394	337	384
Accounts Receivable	12	9.01	7.09	3.27	3.18	1.52	1.18
Prepaid Expenses	6.37	7.54	11	12	5.87	4.48	6.30
Plant, Property, & Equipment, net	1.73	1.83	1.95	2.25	2.02	1.98	1.97
Total Noncurrent Assets	43	58	31	57	77	113	166
Long-Term Investments	28	43	15	40	59	95	148
Other Noncurrent Operating Assets	15	16	16	17	17	18	19
Total Liabilities & Shareholders' Equity	493	427	406	487	517	552	619
Total Liabilities	409	417	358	367	369	361	341
Total Current Liabilities	44	40	32	39	42	36	21
Accounts Payable	3.59	4.89	4.58	6.52	4.76	3.17	3.01
Accrued Expenses	38	34	26	31	35	31	16
Other Current Liabilities	1.89	1.85	1.81	1.74	1.71	1.67	1.60
Total Noncurrent Liabilities	365	377	326	328	327	325	320
Other Noncurrent Operating Liabilities	365	377	326	328	327	325	320
Total Equity & Noncontrolling Interests	84	9.88	48	120	148	191	278
Total Preferred & Common Equity	84	9.88	48	120	148	191	278
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	84	9.88	48	120	148	191	278
Common Stock	821	715	706	695	687	689	708
Retained Earnings	-738	-705	-658	-572	-535	-495	-424
Accumulated Other Comprehensive Income / (Loss)	0.76	-0.42	-0.62	-2.35	-3.61	-3.27	-6.01

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	432.03%	66.78%	-83.72%
EBITDA Growth	30.55%	-43.64%	-106.28%
EBIT Growth	30.09%	-42.79%	-102.80%
NOPAT Growth	30.08%	-42.77%	-102.69%
Net Income Growth	11.24%	-27.11%	-122.72%
EPS Growth	15.79%	-33.04%	-116.59%
Operating Cash Flow Growth	-12.03%	-64.15%	-60.26%
Free Cash Flow Firm Growth	43.80%	-520.40%	-108.46%
Invested Capital Growth	-6.11%	-2.41%	-24.47%
Revenue Q/Q Growth	59.66%	14.69%	129.11%
EBITDA Q/Q Growth	22.40%	-11.68%	5.20%
EBIT Q/Q Growth	22.04%	-10.90%	4.30%
NOPAT Q/Q Growth	22.02%	-10.90%	4.31%
Net Income Q/Q Growth	12.33%	-10.69%	4.54%
EPS Q/Q Growth	15.79%	-12.18%	5.38%
Operating Cash Flow Q/Q Growth	-31.38%	-24.36%	16.57%
Free Cash Flow Firm Q/Q Growth	3.33%	-28.14%	-107.76%
Invested Capital Q/Q Growth	6.34%	0.91%	-2.95%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-123.29%	-944.44%	-1,096.60%
Operating Margin	-125.93%	-958.27%	-1,119.41%
EBIT Margin	-125.91%	-958.29%	-1,119.30%
Profit (Net Income) Margin	-159.11%	-953.66%	-1,251.33%
Tax Burden Percent	100.00%	100.00%	100.02%
Interest Burden Percent	126.36%	99.52%	111.78%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-182.71%	-93.44%	-41.62%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-24.55%	-30.94%	-18.37%
Return on Assets (ROA)	-31.02%	-30.79%	-20.54%
Return on Common Equity (ROCE)	-182.71%	-93.44%	-41.62%
Return on Equity Simple (ROE_SIMPLE)	-204.93%	-185.71%	-49.11%
Net Operating Profit after Tax (NOPAT)	-80	-115	-81
NOPAT Margin	-88.15%	-670.79%	-783.59%
Net Nonoperating Expense Percent (NNEP)	-15.44%	-9.69%	-8.02%
Return On Investment Capital (ROIC_SIMPLE)	-113.54%	-130.63%	-30.75%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	46.44%	244.48%	356.21%
R&D to Revenue	179.49%	813.79%	863.21%
Operating Expenses to Revenue	225.93%	1,058.27%	1,219.41%
Earnings before Interest and Taxes (EBIT)	-115	-164	-115
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-113	-162	-113
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	5.68	6.46	3.36
Price to Tangible Book Value (P/TBV)	5.68	6.46	3.36
Price to Revenue (P/Rev)	4.41	33.18	85.65
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	8.82	28.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-5.28	-2.86	-1.94
Leverage Ratio	5.89	3.03	2.03
Compound Leverage Factor	7.44	3.02	2.27
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-1.25	-1.14	0.71
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.51	10.87	17.16
Quick Ratio	9.38	10.62	16.99
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-60	-107	-17
Operating Cash Flow to CapEx	-37,803.63%	-14,969.02%	-20,556.70%
Free Cash Flow to Firm to Interest Expense	-1.20	-5.94	-0.82
Operating Cash Flow to Interest Expense	-2.70	-6.68	-3.49
Operating Cash Flow Less CapEx to Interest Expense	-2.71	-6.72	-3.50
Efficiency Ratios	-	-	-
Asset Turnover	0.20	0.03	0.02
Accounts Receivable Turnover	3.83	4.15	8.96
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	46.25	8.20	4.71
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	95.20	87.97	40.72
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	95.20	87.97	40.72
Capital & Investment Metrics	-	-	-
Invested Capital	-350	-330	-322
Invested Capital Turnover	-0.27	-0.05	-0.04
Increase / (Decrease) in Invested Capital	-20	-7.75	-63
Enterprise Value (EV)	-18	151	297
Market Capitalization	403	569	881
Book Value per Share	$2.33	$3.32	$9.22
Tangible Book Value per Share	$2.33	$3.32	$9.22
Total Capital	71	88	262
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-421	-418	-584
Capital Expenditures (CapEx)	0.36	0.81	0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.08	-22	-20
Debt-free Net Working Capital (DFNWC)	386	369	421
Net Working Capital (NWC)	386	369	421
Net Nonoperating Expense (NNE)	65	49	48
Net Nonoperating Obligations (NNO)	-421	-418	-584
Total Depreciation and Amortization (D&A)	2.40	2.38	2.34
Debt-free, Cash-free Net Working Capital to Revenue	1.18%	-125.38%	-195.30%
Debt-free Net Working Capital to Revenue	423.37%	2,153.02%	4,094.01%
Net Working Capital to Revenue	423.37%	2,153.02%	4,094.01%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($5.12)	($6.08)	($4.57)
Adjusted Weighted Average Basic Shares Outstanding	28.38M	26.92M	28.17M
Adjusted Diluted Earnings per Share	($5.12)	($6.08)	($4.57)
Adjusted Weighted Average Diluted Shares Outstanding	28.38M	26.92M	28.17M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.67M	26.76M	27.93M
Normalized Net Operating Profit after Tax (NOPAT)	-80	-115	-81
Normalized NOPAT Margin	-88.15%	-670.79%	-783.59%
Pre Tax Income Margin	-159.10%	-953.68%	-1,251.09%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-2.29	-9.09	-5.45
NOPAT to Interest Expense	-1.61	-6.36	-3.82
EBIT Less CapEx to Interest Expense	-2.30	-9.14	-5.47
NOPAT Less CapEx to Interest Expense	-1.61	-6.41	-3.84
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.65%	-30.56%	0.00%

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	378.77%	804.67%	217.08%	422.49%	32.27%	156.61%	184.54%	41.65%	573.39%	-93.81%
EBITDA Growth	78.21%	40.32%	-0.44%	5.05%	-68.92%	-24.51%	-44.44%	-41.29%	20.10%	-392.13%
EBIT Growth	77.10%	39.67%	-0.45%	4.96%	-62.21%	-27.34%	-44.42%	-39.89%	16.62%	-340.25%
NOPAT Growth	77.05%	39.69%	-0.44%	4.95%	-62.23%	-27.33%	-44.40%	-39.85%	16.64%	-338.16%
Net Income Growth	48.39%	11.95%	-17.10%	0.72%	-59.81%	-11.36%	-22.40%	-22.07%	18.82%	-402.58%
EPS Growth	60.38%	19.15%	-14.00%	-3.80%	-70.97%	-19.49%	-30.43%	-20.61%	21.85%	-391.67%
Operating Cash Flow Growth	-94.10%	72.34%	16.08%	-51.63%	-221.47%	-105.52%	-5.23%	-16.91%	57.77%	-153.31%
Free Cash Flow Firm Growth	161.54%	488.34%	-66.01%	-211.44%	-148.18%	-102.24%	-81.34%	-84.12%	-79.71%	2,250.46%
Invested Capital Growth	-6.11%	-12.26%	-12.72%	3.77%	-2.41%	-6.40%	-27.05%	-25.90%	-24.47%	-5,333.45%
Revenue Q/Q Growth	43.63%	173.60%	52.82%	-20.28%	171.40%	-4.10%	151.82%	-79.82%	426.53%	6.33%
EBITDA Q/Q Growth	59.18%	44.20%	4.50%	-21.75%	-11.83%	6.10%	9.72%	-78.19%	17.57%	-8.93%
EBIT Q/Q Growth	57.61%	43.55%	4.46%	-0.16%	-11.68%	6.00%	9.60%	-70.94%	12.33%	-6.61%
NOPAT Q/Q Growth	57.51%	43.56%	4.45%	-0.16%	-11.67%	6.01%	9.59%	-70.95%	12.35%	-6.60%
Net Income Q/Q Growth	33.69%	29.59%	-6.20%	-4.09%	-13.14%	6.37%	9.97%	-67.55%	21.16%	-2.91%
EPS Q/Q Growth	44.74%	33.33%	-4.27%	-3.14%	-12.77%	6.00%	5.06%	-69.89%	21.19%	-2.61%
Operating Cash Flow Q/Q Growth	-560.77%	52.68%	42.76%	-8.45%	5.83%	-43.55%	-3.42%	-129.93%	39.79%	26.50%
Free Cash Flow Firm Q/Q Growth	-46.20%	65.00%	135.74%	-93.96%	-239.51%	-114.44%	17.20%	-16.15%	-84.24%	20.47%
Invested Capital Q/Q Growth	6.34%	2.58%	-18.99%	2.26%	0.91%	2.18%	-1.58%	-4.01%	-2.95%	-16.81%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-20.99%	-73.84%	-362.10%	-579.44%	-461.22%	-1,119.32%	-1,143.15%	-3,188.65%	-361.15%	-2,306.88%
Operating Margin	-22.43%	-75.81%	-367.52%	-587.84%	-467.91%	-1,137.19%	-1,160.20%	-3,231.51%	-381.51%	-2,291.80%
EBIT Margin	-22.38%	-75.83%	-367.52%	-587.87%	-467.93%	-1,137.16%	-1,160.12%	-3,231.80%	-381.57%	-2,291.49%
Profit (Net Income) Margin	-50.53%	-109.44%	-425.30%	-612.01%	-468.75%	-1,124.41%	-1,151.59%	-3,220.89%	-387.97%	-2,591.03%
Tax Burden Percent	99.97%	100.00%	100.02%	100.00%	99.99%	100.00%	100.00%	100.00%	100.09%	100.00%
Interest Burden Percent	225.83%	144.32%	115.70%	104.11%	100.19%	98.88%	99.27%	99.66%	101.59%	113.07%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-182.71%	-161.81%	-214.89%	-136.73%	-93.44%	-74.28%	-63.62%	-52.40%	-41.62%	-40.79%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-4.36%	-8.84%	-23.72%	-28.19%	-15.11%	-30.77%	-26.77%	-58.71%	-6.26%	-19.73%
Return on Assets (ROA)	-9.85%	-12.76%	-27.44%	-29.35%	-15.13%	-30.42%	-26.58%	-58.51%	-6.37%	-22.31%
Return on Common Equity (ROCE)	-182.71%	-161.81%	-214.89%	-136.73%	-93.44%	-74.28%	-63.62%	-52.40%	-41.62%	-40.79%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-196.35%	-1,721.99%	-341.79%	0.00%	-122.79%	-97.01%	-71.55%	0.00%	-48.57%
Net Operating Profit after Tax (NOPAT)	-6.77	-16	-28	-30	-29	-26	-28	-31	-18	-21
NOPAT Margin	-15.70%	-53.07%	-257.27%	-411.49%	-327.53%	-796.03%	-812.14%	-2,262.06%	-267.05%	-1,604.26%
Net Nonoperating Expense Percent (NNEP)	-3.58%	-3.71%	-4.18%	-3.21%	-2.54%	-2.09%	-2.21%	-2.35%	-1.37%	-2.60%
Return On Investment Capital (ROIC_SIMPLE)	-9.55%	-	-	-	-33.48%	-	-	-	-6.94%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	23.64%	35.19%	84.72%	171.86%	114.11%	306.57%	308.67%	787.34%	138.18%	685.38%
R&D to Revenue	98.78%	140.63%	382.80%	515.98%	453.79%	930.62%	951.53%	2,544.18%	343.33%	1,706.42%
Operating Expenses to Revenue	122.43%	175.81%	467.52%	687.84%	567.91%	1,237.19%	1,260.20%	3,331.51%	481.51%	2,391.80%
Earnings before Interest and Taxes (EBIT)	-9.65	-23	-40	-42	-42	-38	-40	-44	-26	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.05	-22	-40	-42	-42	-37	-40	-44	-25	-30
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.68	10.90	69.30	12.61	6.46	3.96	3.63	3.18	3.36	2.59
Price to Tangible Book Value (P/TBV)	5.68	10.90	69.30	12.61	6.46	3.96	3.63	3.18	3.36	2.59
Price to Revenue (P/Rev)	4.41	16.08	22.47	26.25	33.18	31.87	41.65	56.85	85.65	160.44
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	8.07	9.55	10.13	8.82	1.57	3.87	7.64	28.86	28.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.58
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-5.28	-4.45	-5.57	-3.75	-2.86	-2.62	-2.34	-2.15	-1.94	-1.48
Leverage Ratio	5.89	4.79	5.97	4.01	3.03	2.78	2.48	2.26	2.03	1.58
Compound Leverage Factor	13.30	6.91	6.90	4.17	3.04	2.75	2.46	2.25	2.06	1.78
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.53	0.20	-0.65	-0.54	-0.25	-0.13	0.12	0.38	1.19	0.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.51	10.23	9.09	11.53	10.87	10.92	10.53	12.21	17.16	21.39
Quick Ratio	9.38	10.08	8.90	11.20	10.62	10.63	10.39	12.09	16.99	21.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	13	25	15	-42	-22	-6.40	44	38	45	286
Operating Cash Flow to CapEx	-25,350.57%	-28,828.57%	-64,612.12%	-137,974.07%	-12,267.50%	-22,514.81%	-13,373.16%	-14,038.86%	-6,105.71%	-35,494.00%
Free Cash Flow to Firm to Interest Expense	0.77	1.61	1.38	-6.68	-4.38	-1.45	10.18	8.73	10.62	46.68
Operating Cash Flow to Interest Expense	-3.83	-0.65	-1.95	-5.90	-6.93	-8.23	-5.83	-5.67	-2.51	-2.89
Operating Cash Flow Less CapEx to Interest Expense	-3.85	-0.66	-1.95	-5.90	-6.98	-8.27	-5.87	-5.71	-2.55	-2.90
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.20	0.12	0.06	0.05	0.03	0.03	0.02	0.02	0.02	0.01
Accounts Receivable Turnover	3.83	7.39	5.00	5.33	4.15	6.73	6.14	8.75	8.96	4.63
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	46.25	28.72	15.81	11.67	8.20	7.08	6.34	5.16	4.71	2.05
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	95.20	49.36	73.00	68.45	87.97	54.27	59.47	41.72	40.72	78.89
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	95.20	49.36	73.00	68.45	87.97	54.27	59.47	41.72	40.72	78.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-350	-374	-384	-322	-330	-333	-340	-335	-322	-313
Invested Capital Turnover	-0.27	-0.16	-0.08	-0.07	-0.05	-0.05	-0.04	-0.04	-0.04	-0.03
Increase / (Decrease) in Invested Capital	-20	-41	-43	13	-7.75	-20	-72	-69	-63	-307
Enterprise Value (EV)	-18	462	291	233	151	24	50	82	297	130
Market Capitalization	403	920	685	603	569	477	539	608	881	720
Book Value per Share	$2.33	$3.07	$0.36	$1.79	$3.32	$4.54	$5.60	$6.84	$9.22	$9.83
Tangible Book Value per Share	$2.33	$3.07	$0.36	$1.79	$3.32	$4.54	$5.60	$6.84	$9.22	$9.83
Total Capital	71	84	9.88	48	88	120	148	191	262	278
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-421	-458	-393	-370	-418	-453	-489	-526	-584	-590
Capital Expenditures (CapEx)	0.26	0.04	0.03	0.03	0.28	0.16	0.19	0.18	0.18	0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.08	-25	-24	-15	-22	-24	-33	-30	-20	-14
Debt-free Net Working Capital (DFNWC)	386	405	327	340	369	389	397	401	421	429
Net Working Capital (NWC)	386	405	327	340	369	389	397	401	421	429
Net Nonoperating Expense (NNE)	15	17	18	14	13	11	12	13	8.23	13
Net Nonoperating Obligations (NNO)	-421	-458	-393	-370	-418	-453	-489	-526	-584	-590
Total Depreciation and Amortization (D&A)	0.60	0.60	0.60	0.61	0.60	0.59	0.59	0.59	1.39	-0.20
Debt-free, Cash-free Net Working Capital to Revenue	1.18%	-44.28%	-78.34%	-63.34%	-125.38%	-161.93%	-251.89%	-278.66%	-195.30%	-302.56%
Debt-free Net Working Capital to Revenue	423.37%	708.04%	1,072.85%	1,481.24%	2,153.02%	2,599.08%	3,068.45%	3,754.18%	4,094.01%	9,563.05%
Net Working Capital to Revenue	423.37%	708.04%	1,072.85%	1,481.24%	2,153.02%	2,599.08%	3,068.45%	3,754.18%	4,094.01%	9,563.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.63)	($1.14)	($1.71)	($1.64)	($1.59)	($1.41)	($1.50)	($1.58)	($0.93)	($1.18)
Adjusted Weighted Average Basic Shares Outstanding	28.38M	28.89M	27.36M	26.80M	26.92M	26.55M	26.63M	27.95M	28.17M	28.29M
Adjusted Diluted Earnings per Share	($0.63)	($1.14)	($1.71)	($1.64)	($1.59)	($1.41)	($1.50)	($1.58)	($0.93)	($1.18)
Adjusted Weighted Average Diluted Shares Outstanding	28.38M	28.89M	27.36M	26.80M	26.92M	26.55M	26.63M	27.95M	28.17M	28.29M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.67M	30.43M	27.45M	27.32M	26.76M	26.58M	26.55M	26.49M	27.93M	28.43M
Normalized Net Operating Profit after Tax (NOPAT)	-6.77	-16	-28	-30	-29	-26	-28	-31	-18	-21
Normalized NOPAT Margin	-15.70%	-53.07%	-257.27%	-411.49%	-327.53%	-796.03%	-812.14%	-2,262.06%	-267.05%	-1,604.26%
Pre Tax Income Margin	-50.54%	-109.44%	-425.22%	-612.01%	-468.80%	-1,124.41%	-1,151.59%	-3,220.89%	-387.62%	-2,591.03%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.55	-1.48	-3.68	-6.68	-8.50	-8.52	-9.21	-10.24	-6.11	-4.83
NOPAT to Interest Expense	-0.39	-1.03	-2.58	-4.68	-5.95	-5.96	-6.45	-7.17	-4.28	-3.38
EBIT Less CapEx to Interest Expense	-0.57	-1.48	-3.68	-6.69	-8.56	-8.55	-9.25	-10.28	-6.15	-4.84
NOPAT Less CapEx to Interest Expense	-0.40	-1.04	-2.58	-4.68	-6.01	-6.00	-6.49	-7.21	-4.32	-3.39
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.65%	-0.22%	0.00%	-7.64%	-30.56%	-33.82%	-34.72%	-27.45%	0.00%	0.00%

Frequently Asked Questions About AnaptysBio's Financials

When does AnaptysBio's fiscal year end?

According to the most recent income statement we have on file, AnaptysBio's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AnaptysBio's net income changed over the last 2 years?

AnaptysBio's net income appears to be on an upward trend, with a most recent value of -$145.23 million in 2024, rising from -$128.72 million in 2022. The previous period was -$163.62 million in 2023. View AnaptysBio's forecast to see where analysts expect AnaptysBio to go next.

What is AnaptysBio's operating income?

AnaptysBio's total operating income in 2024 was -$114.95 million, based on the following breakdown:

Total Gross Profit: $91.28 million
Total Operating Expenses: $206.23 million

How has AnaptysBio revenue changed over the last 2 years?

Over the last 2 years, AnaptysBio's total revenue changed from $10.29 million in 2022 to $91.28 million in 2024, a change of 787.3%.

How much debt does AnaptysBio have?

AnaptysBio's total liabilities were at $412.97 million at the end of 2024, a 13.4% increase from 2023, and a 18.6% increase since 2022.

How much cash does AnaptysBio have?

In the past 2 years, AnaptysBio's cash and equivalents has ranged from $35.97 million in 2023 to $123.08 million in 2024, and is currently $123.08 million as of their latest financial filing in 2024.

How has AnaptysBio's book value per share changed over the last 2 years?

Over the last 2 years, AnaptysBio's book value per share changed from 9.22 in 2022 to 2.33 in 2024, a change of -74.7%.

Related Companies

This page (NASDAQ:ANAB) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Financials

Frequently Asked Questions About AnaptysBio's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Financials

Annual Income Statements for AnaptysBio

Quarterly Income Statements for AnaptysBio

Annual Cash Flow Statements for AnaptysBio

Quarterly Cash Flow Statements for AnaptysBio

Annual Balance Sheets for AnaptysBio

Quarterly Balance Sheets for AnaptysBio

Annual Metrics And Ratios for AnaptysBio

Quarterly Metrics And Ratios for AnaptysBio

Frequently Asked Questions About AnaptysBio's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools